v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash Flows from Operating Activities:    
Net loss $ (10,432,083) $ (222,122)
Less: net income (loss) from discontinued operations, net of tax (5,392,785) (414,585)
Net income (loss) from continuing operations (5,039,298) 192,463
Adjustments to reconcile net loss to net cash flows used in operating activities:    
Depreciation and amortization 81,532 728,176
Stock based compensation 112,586 23,565
Non-cash interest expense 7,535 685,158
Gain on extinguishment of liabilities (63,259) (2,230,716)
Non-cash litigation settlement 384,000
Change in fair value of warrant derivative liability 289,361 (3,373,080)
(Increase) decrease in:    
Accounts receivable – trade (535,431) 384,511
Accounts receivable – other (including related party) (3,886) 153,827
Inventories (79,098) 176,660
Prepaid expenses (491,717) 128,413
Operating lease right of use assets 90,073 (1,098,592)
Other assets 39,998 510,000
Increase (decrease) in:    
Accounts payable 500,729 (3,468,491)
Accrued expenses 890,894 (110,904)
Accrued interest - related party 177,899
Income taxes payable (10,441)
Operating lease obligations (7,705) 857,279
Deferred revenues 1,153
Net cash used in operating activities – continuing operation (3,832,974) (6,263,832)
Net cash provided by (used in) operating activities – discontinued operation 68,635 (2,380,274)
Cash Flows from Investing Activities:    
Purchases of property, plant and equipment (182,047) (218,474)
Purchases of intangible assets (46,621) (10,786)
Proceeds from sale of Nobility Healthcare 100,000
Net cash used in investing activities – continuing operation (128,668) (229,260)
Net cash used in investing activities – discontinued operation (12,074) (83,781)
Cash Flows from Financing Activities:    
Net proceeds from issuance of common stock under equity line of credit 4,004,659
Net proceeds of February 2025 public equity offering with detachable warrants 14,308,300
Net proceeds of unsecured promissory note – Entertainment 600,000
Payments of related party note payable (162,000)
Payments on Commercial Extension of Credit – Entertainment (100,000)
Payments on Senior Secured Promissory Notes – Corporate (3,600,000)
Payments on Merchant Advances – Corporate (1,922,750)
Payments on unsecured promissory note – Entertainment (25,000)
Principal payment on EIDL loan (1,754) (1,690)
Proceeds from issuance of common shares upon exercise of Series B warrants 3,793
Net cash provided by financing activities – continuing operation 3,977,905 9,125,653
Net cash provided by financing activities – discontinued operation
Net increase (decrease) in cash, cash equivalents and restricted cash 72,824 168,506
Cash and cash equivalents, beginning of period 757,369 454,314
Cash and cash equivalents, end of period 830,193 622,820
Supplemental disclosures of cash flow information:    
Cash payments for interest 35,689 26,896
Cash payments for income taxes 10,441 5,198
Supplemental disclosures of non-cash investing and financing activities:    
Note receivable received in connection with sale of discontinued operation, at initial fair value. 1,117,303
Transition to additional paid-in capital upon conversion of convertible notes 1,357,253
Issuance of common stock upon conversion of convertible notes payable 112
Deemed capital contribution related to modification of notes payable - related party 1,871,994
Fair value of warrants issued with sale of shares 6,748,425
Transition of warrant derivative liability to equity upon exercise of warrants 7,928,030
Common stock issuable in settlement of litigation 384,000
Issuance costs withheld from ELOC proceeds 638,282
Issuance of common stock upon exercise of pre-funded warrants $ 49